Literature DB >> 17968495

Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans.

Nobuaki Ito1, Seiji Fukumoto, Yasuhiro Takeuchi, Shu Takeda, Hisanori Suzuki, Takeyoshi Yamashita, Toshiro Fujita.   

Abstract

Fibroblast growth factor (FGF)23 was identified as a humoral factor involved in the development of several hypophosphatemic diseases. Subsequent studies indicated that FGF23 is a hormone regulating serum phosphate level. However, it is still unknown how the production and serum level of FGF23 are regulated. This study was designed to determine whether acute changes of serum phosphate modulate FGF23 levels in human. Four healthy volunteers participated in the study. In the phosphate infusion study, dibasic potassium phosphate was infused at a rate of 10 mEq/h for 4 h, and serum FGF23 levels were measured for up to 6 h after the start of the infusion. In the carbohydrate study, partially hydrolyzed starch corresponding to 150 g glucose was ingested and FGF23 levels were measured similarly for 6 h. Phosphate infusion significantly increased and carbohydrate ingestion decreased serum phosphate levels, respectively. However, FGF23 did not change by these maneuvers. It is concluded that acute changes of serum phosphate do not modify FGF23 levels in the healthy human.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17968495     DOI: 10.1007/s00774-007-0779-3

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  23 in total

1.  Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.

Authors:  Serge L Ferrari; Jean-Philippe Bonjour; René Rizzoli
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

2.  Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism.

Authors:  Takashi Shimada; Yuji Yamazaki; Motoo Takahashi; Hisashi Hasegawa; Itaru Urakawa; Takeshi Oshima; Kaori Ono; Makoto Kakitani; Kazuma Tomizuka; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Am J Physiol Renal Physiol       Date:  2005-07-05

3.  A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis.

Authors:  Tobias Larsson; Xijie Yu; Siobhan I Davis; Mohamad S Draman; Sean D Mooney; Michael J Cullen; Kenneth E White
Journal:  J Clin Endocrinol Metab       Date:  2005-02-01       Impact factor: 5.958

4.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

5.  A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis.

Authors:  Kaori Araya; Seiji Fukumoto; Rebecca Backenroth; Yasuhiro Takeuchi; Kounosuke Nakayama; Nobuaki Ito; Nozomi Yoshii; Yuji Yamazaki; Takeyoshi Yamashita; Justin Silver; Takashi Igarashi; Toshiro Fujita
Journal:  J Clin Endocrinol Metab       Date:  2005-07-19       Impact factor: 5.958

6.  Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.

Authors:  Despina Sitara; Mohammed S Razzaque; Martina Hesse; Subbiah Yoganathan; Takashi Taguchi; Reinhold G Erben; Harald Jüppner; Beate Lanske
Journal:  Matrix Biol       Date:  2004-11       Impact factor: 11.583

7.  Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia.

Authors:  Yasuhiro Takeuchi; Hisanori Suzuki; Sayoko Ogura; Rie Imai; Yuji Yamazaki; Takeyoshi Yamashita; Yoshinari Miyamoto; Hiroshi Okazaki; Kozo Nakamura; Kazuhiko Nakahara; Seiji Fukumoto; Toshiro Fujita
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

8.  FGF-23 is elevated by chronic hyperphosphatemia.

Authors:  A Gupta; K Winer; M J Econs; S J Marx; M T Collins
Journal:  J Clin Endocrinol Metab       Date:  2004-09       Impact factor: 5.958

9.  Serum FGF23 levels in normal and disordered phosphorus homeostasis.

Authors:  Thomas J Weber; Shiguang Liu; Olafur S Indridason; L Darryl Quarles
Journal:  J Bone Miner Res       Date:  2003-07       Impact factor: 6.741

10.  Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.

Authors:  Takashi Shigematsu; Junichiro James Kazama; Takeyoshi Yamashita; Seiji Fukumoto; Tatsuo Hosoya; Fumitake Gejyo; Masafumi Fukagawa
Journal:  Am J Kidney Dis       Date:  2004-08       Impact factor: 8.860

View more
  55 in total

Review 1.  Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.

Authors:  Marie Courbebaisse; Beate Lanske
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

Review 2.  Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation.

Authors:  Wacharee Seeherunvong; Myles Wolf
Journal:  Pediatr Transplant       Date:  2010-10-08

Review 3.  Recent advances in renal phosphate handling.

Authors:  Emily G Farrow; Kenneth E White
Journal:  Nat Rev Nephrol       Date:  2010-02-23       Impact factor: 28.314

4.  Effects of dietary phosphate and calcium intake on fibroblast growth factor-23.

Authors:  Marc G Vervloet; Frans J van Ittersum; Rahel M Büttler; Annemieke C Heijboer; Marinus A Blankenstein; Piet M ter Wee
Journal:  Clin J Am Soc Nephrol       Date:  2010-10-28       Impact factor: 8.237

Review 5.  Biomarkers in chronic kidney disease, from kidney function to kidney damage.

Authors:  Salvador Lopez-Giacoman; Magdalena Madero
Journal:  World J Nephrol       Date:  2015-02-06

Review 6.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

Review 7.  Novel mechanisms in the regulation of phosphorus homeostasis.

Authors:  Theresa Berndt; Rajiv Kumar
Journal:  Physiology (Bethesda)       Date:  2009-02

Review 8.  Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism.

Authors:  Makoto Kuro-o
Journal:  Nat Rev Nephrol       Date:  2013-06-18       Impact factor: 28.314

9.  The human response to acute enteral and parenteral phosphate loads.

Authors:  Roberto Scanni; Matthias vonRotz; Sigrid Jehle; Henry N Hulter; Reto Krapf
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

Review 10.  Fibrous dysplasia and fibroblast growth factor-23 regulation.

Authors:  Alison M Boyce; Nisan Bhattacharyya; Michael T Collins
Journal:  Curr Osteoporos Rep       Date:  2013-06       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.